永利77402官方网

楂樺畨鎱

姣曚笟浜庡崕涓滃笀鑼冨ぇ瀛︾敓鍛界瀛﹀闄紝鑾峰緱鐢熺悊瀛﹀崥澹浣嶃傜洰鍓嶄换鑱屼簬涓浗绉戝闄笂娴疯嵂鐗╃爺绌舵墍锛屾媴浠荤爺绌跺憳銆傚湪鐧炬瀬寮樼儴锛堝崡閫氾級鍖昏嵂绉戞妧鏈夐檺鍏徃浠绘荤粡鐞嗐

鐮旂┒鏂瑰悜锛鎶楄娑茶偪鐦ょ殑鏂拌嵂鐮斿彂

涓昏鑷村姏浜庢姉琛娑茶偪鐦ょ殑鏂拌嵂鐮斿彂銆傚弬涓庡椤硅嵂鐗╃爺鍙戦」鐩紝鍏朵腑鍙備笌鐨2涓」鐩凡鍒嗗埆浜2016骞磋幏寰桟FDA鐨勪复搴婃壒浠跺拰2020骞磋幏寰桸MPA鐨勪复搴婅瘯楠岀爺绌堕氱煡涔︼紝鍙﹀鑾峰緱澶氫釜鏋佸叿娼滃姏鐨勫欓夊寲鍚堢墿杩涘叆绯荤粺鐨勪复搴婂墠璇勪环銆傚鍊欓夊寲鍚堢墿鐨勭爺鍙戜互鍙婂鑽墿鐨勪复搴婂墠鐮旂┒鏈夎緝鍏ㄩ潰鐨勮璇嗐傜浉鍏崇爺绌舵垚鏋滃彂琛ㄥ湪 BBA General Subjects锛孫rganic letters锛孧arine drugs锛孉ntiviral research锛孒elv Chim Acta锛孋hemMedChem 绛夋潅蹇楋紝绗竴浣滆5 绡囷紝鍙備笌鍙戣〃 11 绡囷紝涓撳埄鐢宠 6 椤癸紝涓绘寔鎴栧弬鍔犵鐮旈」鐩紙璇鹃锛夊強浜烘墠璁″垝椤圭洰 6 椤广

浠ｈ〃鎬ц鏂囷細

1. X. Liu^#, Y. Hu^#, A. H.Gao^#, M. Xu, L. Gao, L. Xu, Y. Zhou, J. Gao, Q. Ye, J. Li, Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors, Bioorganic & medicinal chemistry, 27 (2019) 589-603.
2. X. Ji, L. Song, L. Sheng, A.H. Gao, Y. Zhao, S. Han, Y. Zhang, C. Zhu, S. Zhao, Z. Wang, B. Xu, L. Li, J. Li, N. Tan, B. Zhao, Cyclopeptide RA-V Inhibits Organ Enlargement and Tumorigenesis Induced by YAP Activation, Cancers, 10 (2018).
3. Y. Hu^#, A.H. Gao^#, H. Liao, M. Zhang, G. Xu, L. Gao, L. Xu, Y. Zhou, J. Gao, Q. Ye, J. Li, 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation, Archiv der Pharmazie, 351 (2018) e1800039.  
4. C.J. Gong^#, A.H. Gao^#, Y.M. Zhang, M.B. Su, F. Chen, L. Sheng, Y.B. Zhou, J.Y. Li, J. Li, F.J. Nan, Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy, European journal of medicinal chemistry, 112 (2016) 81-90.
5. A.H. Gao^#, Y.Y. Fu, K.Z. Zhang, M. Zhang, H.W. Jiang, L.X. Fan, F.J. Nan, C.G. Yuan, J. Li, Y.B. Zhou, J.Y. Li, Azoxystrobin, a mitochondrial complex III Qo site inhibitor, exerts beneficial metabolic effects in vivo and in vitro, Biochimica et biophysica acta, 1840 (2014) 2212-2221.銆

鍏朵粬绉戠爺鎴愭灉锛堜笓鍒╃瓑锛

1. Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, and Anhui GAO锛孊RUTON’STYROSINE KINASE INHIBITORS锛孉pplication Number: US 62/241,184 , Status Date: 10-14-2015锛汸CT/US16/55096. 宸叉巿鏉冦
2. Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, and Anhui GAO锛孊RUTON’STYROSINE KINASE INHIBITORS锛孉pplication Number: US 62/281,252 , Status Date: 01-21-2016锛汸CT/US17/13815.
3. 鍙堕潚锛屾潕浣筹紝鍛ㄥ畤娉紝楂樺畨鎱锛岄珮绔嬩俊锛岃儭鍦嗗渾锛屽姳闆紝楂樺缓鑽ｏ紱涓绉嶅弻鑺冲熀椹潵閰颁簹鑳虹被鍖栧悎鐗╁強鍏惰嵂瀛︿笂鍙帴鍙楃殑鐩愬強鍏跺埗澶囨柟娉曞拰搴旂敤锛屼腑鍥界敵璇蜂笓鍒╁彿锛 201610270132.5 鐢宠鏃ワ細2016骞4鏈26鏃ワ紱宸叉巿鏉冦
4. 鍒樻粩锛屾潕浣筹紝鑳℃案娲诧紝鍛ㄥ畤娉紝钁ｆ檽姝︼紝楂樺畨鎱锛屽畫鍝侀ザ锛岀涔愪粰锛 2#鍙栦唬鑺崇幆#鍢у暥绫昏鐢熺墿鍙婂埗澶囧拰搴旂敤锛屼腑鍥界敵璇蜂笓鍒╁彿锛欳N201610988060.8锛岀敵璇锋棩锛2016.11.10銆傚凡鎺堟潈銆
5. 鍒樻粩锛屾潕浣筹紝鑳℃案娲诧紝楂樺畨鎱锛岃懀鏅撴锛屽懆瀹囨尝锛屽畫鍝侀ザ锛岀涔愪粰锛 2#澶氬彇浠ｈ姵鐜#鍢у暥绫昏鐢熺墿鍙婂埗澶囧拰鍖昏嵂鐢ㄩ旓紝涓浗涓撳埄锛屼腑鍥界敵璇蜂笓鍒╁彿锛欳N201610988036.4锛岀敵璇锋棩锛2016.11.10銆傚凡鎺堟潈銆